{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T04:53:08Z","timestamp":1696308788499},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,12,27]],"date-time":"2013-12-27T00:00:00Z","timestamp":1388102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s12072-013-9496-2","type":"journal-article","created":{"date-parts":[[2013,12,26]],"date-time":"2013-12-26T04:21:52Z","timestamp":1388031712000},"page":"285-292","source":"Crossref","is-referenced-by-count":4,"title":["Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C"],"prefix":"10.1007","volume":"8","author":[{"given":"Toru","family":"Ikegami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoharu","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Toshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Aishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takasuke","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,27]]},"reference":[{"key":"9496_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/lt.23555","volume":"19","author":"M Berenguer","year":"2013","unstructured":"Berenguer M, Roche B, Aguilera V, Duclos-Vall\u00e9e JC, Navarro L, Rub\u00edn A, et al. Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach. Liver Transpl 2013;19:69\u201377","journal-title":"Liver Transpl"},{"key":"9496_CR2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/TP.0b013e3181d2bfca","volume":"90","author":"Y Ueda","year":"2010","unstructured":"Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 2010;90:661\u2013665","journal-title":"Transplantation"},{"key":"9496_CR3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jhep.2006.12.017","volume":"46","author":"M Angelico","year":"2007","unstructured":"Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007;46:1009\u20131017","journal-title":"J Hepatol"},{"key":"9496_CR4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1053\/j.gastro.2012.01.030","volume":"142","author":"J Levitsky","year":"2012","unstructured":"Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012;142:1132\u20131139","journal-title":"Gastroenterology"},{"key":"9496_CR5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2010.11.012","volume":"55","author":"N Selzner","year":"2011","unstructured":"Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011;55:207\u2013217","journal-title":"J Hepatol"},{"key":"9496_CR6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.dld.2008.09.015","volume":"41","author":"M Merli","year":"2009","unstructured":"Merli M, Gentili F, Giusto M, Attili AF, Corradini SG, Mennini G, et al. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis 2009;41:345\u2013349","journal-title":"Dig Liver Dis"},{"key":"9496_CR7","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1600-6143.2012.04022.x","volume":"12","author":"Y Soejima","year":"2012","unstructured":"Soejima Y, Shirabe K, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, et al. Left lobe living donor liver transplantation in adults. Am J Transpl 2012;12:1877\u20131885","journal-title":"Am J Transpl"},{"key":"9496_CR8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jamcollsurg.2008.10.034","volume":"208","author":"T Ikegami","year":"2009","unstructured":"Ikegami T, Toshima T, Takeishi K, Soejima Y, Kawanaka H, Yoshizumi T, et al. Bloodless splenectomy during liver transplantation for terminal liver diseases with portal hypertension. J Am Coll Surg 2009;208:e1\u2013e4","journal-title":"J Am Coll Surg"},{"key":"9496_CR9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/hepr.12003","volume":"43","author":"T Ikegami","year":"2013","unstructured":"Ikegami T, Shirabe K, Fukuhara T, Furusyo N, Kotoh K, Kato M, et al. Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation. Hepatol Res 2013;43:621\u2013629","journal-title":"Hepatol Res"},{"key":"9496_CR10","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1053\/j.gastro.2010.07.058","volume":"139","author":"T Fukuhara","year":"2010","unstructured":"Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010;139:1577\u20131585","journal-title":"Gastroenterology"},{"key":"9496_CR11","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/lt.21890","volume":"15","author":"AJ Demetris","year":"2009","unstructured":"Demetris AJ. Evolution of hepatitis C virus in liver allografts. Liver Transpl 2009;15:S35\u2013S41","journal-title":"Liver Transpl"},{"key":"9496_CR12","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/lt.20706","volume":"12","author":"N Kontorinis","year":"2006","unstructured":"Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006;12:827\u2013830","journal-title":"Liver Transpl"},{"key":"9496_CR13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2006.092064","volume":"56","author":"S Berardi","year":"2007","unstructured":"Berardi S, Lodato F, Gramenzi A, D\u2019Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56:237\u2013242","journal-title":"Gut"},{"key":"9496_CR14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/01.tp.0000269609.08495.45","volume":"84","author":"CM Stanca","year":"2007","unstructured":"Stanca CM, Fiel MI, Kontorinis N, Agarwal K, Emre S, Schiano TD. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007;84:180\u2013186","journal-title":"Transplantation"},{"key":"9496_CR15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/lt.21447","volume":"14","author":"MI Fiel","year":"2008","unstructured":"Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008;14:861\u2013871","journal-title":"Liver Transpl"},{"key":"9496_CR16","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/lt.21949","volume":"15","author":"SC Ward","year":"2009","unstructured":"Ward SC, Schiano TD, Thung SN, Fiel MI. Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case\u2013control study showing poor outcome and predictive features in the liver explant. Liver Transpl 2009;15:1826\u20131833","journal-title":"Liver Transpl"},{"key":"9496_CR17","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/00007890-200111270-00018","volume":"72","author":"K Washburn","year":"2001","unstructured":"Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001;72:1675\u20131679","journal-title":"Transplantation"},{"key":"9496_CR18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2007.07.023","volume":"47","author":"M Vivarelli","year":"2007","unstructured":"Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007;47:793\u2013798","journal-title":"J Hepatol"},{"key":"9496_CR19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/lt.21182","volume":"13","author":"GB Klintmalm","year":"2007","unstructured":"Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007;13:1521\u20131531","journal-title":"Liver Transpl"},{"key":"9496_CR20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/lt.23559","volume":"19","author":"EC Verna","year":"2013","unstructured":"Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS Jr. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl 2013;19:78\u201388","journal-title":"Liver Transpl"},{"key":"9496_CR21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0168-8278(98)80224-9","volume":"28","author":"M Berenguer","year":"1998","unstructured":"Berenguer M, Prieto M, C\u00f3rdoba J, Ray\u00f3n JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998;28:756\u2013763","journal-title":"J Hepatol"},{"key":"9496_CR22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jhep.2011.06.031","volume":"56","author":"DN Samonakis","year":"2012","unstructured":"Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 2012;56:973\u2013983","journal-title":"J Hepatol"},{"key":"9496_CR23","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1097\/TP.0b013e318283a82e","volume":"95","author":"T Ikegami","year":"2013","unstructured":"Ikegami T, Shirabe K, Yoshizumi T, Furusyo N, Kotoh K, Kato M, et al. Impact of conversion from pegylated interferon-\u03b12b to interferon-\u03b12a for treating recurrent hepatitis C after liver transplantation. Transplantation 2013;95:e38\u2013e42","journal-title":"Transplantation"},{"key":"9496_CR24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10620-005-2563-3","volume":"50","author":"SK Herrine","year":"2005","unstructured":"Herrine SK, Brown RS Jr, Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 2005;50:719\u2013726","journal-title":"Dig Dis Sci"},{"key":"9496_CR25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1471-230X-12-158","volume":"12","author":"T Motomura","year":"2012","unstructured":"Motomura T, Shirabe K, Furusyo N, Yoshizumi T, Ikegami T, Soejima Y, et al. Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype. BMC Gastroenterol 2012;12:158. doi: 10.1186\/1471-230X-12-158","journal-title":"BMC Gastroenterol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-013-9496-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-013-9496-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-013-9496-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:37:15Z","timestamp":1559446635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-013-9496-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,27]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["9496"],"URL":"https:\/\/doi.org\/10.1007\/s12072-013-9496-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,27]]}}}